ErbB2 Targeted Epigenetic Modulation: Anti-tumor Efficacy of the ADC Trastuzumab-HDACi ST8176AA1

ErbB2 Targeted Epigenetic Modulation: Anti-tumor Efficacy of the ADC Trastuzumab-HDACi ST8176AA1

Targeted therapy using monoclonal antibodies conjugated to toxins is gaining space in the treatment of cancer. Here, we report the anti-tumor effect of a new antibody drug conjugate (ADC) delivering a HDAC inhibitor to ErbB2+ solid tumors. Trastuzumab was partially reduced with tris [2-carboxyethyl]...

Full description

Bibliographic Details
Main Authors: Ferdinando Maria Milazzo, Loredana Vesci, Anna Maria Anastasi, Caterina Chiapparino, Antonio Rosi, Giuseppe Giannini, Maurizio Taddei, Elena Cini, Valentina Faltoni, Elena Petricci, Gianfranco Battistuzzi, Laura Salvini, Valeria Carollo, Rita De Santis
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-01-01
Series:Frontiers in Oncology
Subjects:
ADC (antibody drug conjugate)
HDACi (Histone deacetylase inhibitor)
trastuzumab
ErbB2
solid tumors
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01534/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.01534/full

Similar Items